2. Search Result
Search Result
Results for "

hGLP-1R

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-177295
    Naperiglipron

    LY3549492

    		 GLP Receptor Phosphodiesterase (PDE) Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research [1].
    Naperiglipron
  • HY-143312D
    (R)-V-0219 hydrochloride

    		GLP Receptor Metabolic Disease
    (R)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R [1].
    (R)-V-0219 hydrochloride
  • HY-143312E
    (S)-V-0219 hydrochloride

    		GLP Receptor Metabolic Disease
    (S)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 hydrochloride is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice [1].
    (S)-V-0219 hydrochloride
  • HY-173479
    GLP-1R agonist 30

    		GLP Receptor Cardiovascular Disease Metabolic Disease
    GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC50 of 0.048 nM. GLP-1R has excellent selectivity, with EC50 greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice [1].
    GLP-1R agonist 30
  • HY-P10327
    PP18

    		GLP Receptor Metabolic Disease
    PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC50 values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR [1].
    PP18
  • HY-143312B
    (R)-V-0219

    		GLP Receptor Metabolic Disease
    (R)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R [1].
    (R)-V-0219
  • HY-172411
    GLP-1R agonist 29

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 29 (Compound 20) is the agonist for GLP-1R that induces hGLP-1R mediated cAMP stimulation with an EC50 of 0.018 nM. GLP-1R agonist 29 exhibits good pharmacokinetics characteristics with good body exposure of AUC0-∞,sc of 77688 ng·h/mL [1].
    GLP-1R agonist 29
  • HY-168481
    GLP-1R agonist 27

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. GLP-1R agonist 27 promots cyclic adenosine monophosphate (cAMP) accumulation. GLP-1R agonist 27 reduces blood glucose levels and food intake. GLP-1R agonist 27 has the potential for the research of obesity and type 2 diabetes mellitus (T2DM) [1].
    GLP-1R agonist 27
  • HY-143312C
    (S)-V-0219

    		GLP Receptor Metabolic Disease
    (S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice [1].
    (S)-V-0219
  • HY-183693
    GLP-1 receptor agonist 21

    		GLP Receptor Metabolic Disease
    GLP-1 receptor agonist 21 is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of 0.64 nM. GLP-1 receptor agonist 21 reduces blood glucose levels and suppresses cumulative food consumption in diabetic mice. GLP-1 receptor agonist 21 can be used for the researches of type 2 diabetes and obesity [1].
    GLP-1 receptor agonist 21
  • HY-183694
    GLP-1 receptor agonist 22

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    GLP-1 receptor agonist 22 is an orally active GLP-1 receptor agonist. GLP-1 receptor agonist 22 promotes the accumulation of cAMP. GLP-1 receptor agonist 22 reduces blood glucose levels and inhibits feeding behavior in human glucagon-like peptide-1 receptor knock-in mice. GLP-1 receptor agonist 22 can be used in the research of type 2 diabetes and obesity [1].
    GLP-1 receptor agonist 22

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: